xinbang phar.(SZ:002390)2025-05-13 01:12Group 1: Company Performance and Challenges - The company faced a decline in gross margin and net profit due to factors such as national drug procurement policies, adjustments in medical insurance settlement methods, and rising raw material prices in 2024 [3] - In Q4 2024, the company reported a net loss of CNY 75.208 million, primarily due to decreased revenue and gross margin in the pharmaceutical distribution and medical services sectors, along with increased non-recurring losses [6] - The management acknowledged the concerns of investors regarding the company's performance and emphasized the importance of protecting investor rights [3] Group 2: Strategic Responses and Future Plans - The management is actively addressing challenges by enhancing medical service quality, optimizing long-term customer accounts in the pharmaceutical distribution sector, and promoting the development of traditional Chinese medicine [3] - The company plans to continue its efforts in market management and operational compliance to ensure long-term development and value creation for investors [3] - The company has implemented a share buyback and cash dividend strategy, distributing a total of CNY 171.2894 million in cash dividends in 2024, which accounted for 168.96% of the net profit attributable to shareholders [6] Group 3: Subsidiary Operations and Legal Matters - The subsidiary, Keke Pharmaceutical, is currently operating normally despite being under investigation, and the company will disclose any significant developments as required [4] - The management reassured investors that the ongoing legal matters would not adversely affect the subsidiary's operations or the company's overall performance [6]